Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.verified

SUPN

Price:

$36.22

Market Cap:

$2.00B

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hy...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2012-05-01

Stock Exchange

NASDAQ

Ticker

SUPN

The PE Ratio as of November 2024 (TTM) for Supernus Pharmaceuticals, Inc. (SUPN) is 33.85

According to Supernus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 33.85. This represents a change of -96.67% compared to the average of 1.02K of the last 4 quarters.

Supernus Pharmaceuticals, Inc. (SUPN) Historical PE Ratio (quarterly & annually)

How has SUPN PE Ratio performed in the past?

The mean historical PE Ratio of Supernus Pharmaceuticals, Inc. over the last ten years is 140.90. The current 33.85 PE Ratio has changed 2.30% with respect to the historical average. Over the past ten years (40 quarters), SUPN's PE Ratio was at its highest in in the March 2024 quarter at 3.70K. The PE Ratio was at its lowest in in the June 2023 quarter at -492.89.

Quarterly (TTM)
Annual

Average

140.90

Median

23.32

Minimum

10.43

Maximum

1.20K

Supernus Pharmaceuticals, Inc. (SUPN) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Supernus Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 3.70%

Maximum Annual PE Ratio = 1.20K

Minimum Annual Increase = -778.93%

Minimum Annual PE Ratio = 10.43

Quarterly (TTM)
Annual
YearPE RatioChange
20231.20K3.70%
202231.538.79%
202128.98177.94%
202010.43-5.17%
201911.00-29.33%
201815.56-55.93%
201735.31157.84%
201613.69-69.93%
201545.53157.95%
201417.65-778.93%

Supernus Pharmaceuticals, Inc. (SUPN) Average PE Ratio

How has SUPN PE Ratio performed in the past?

The current PE Ratio of Supernus Pharmaceuticals, Inc. (SUPN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

419.94

5-year avg

256.25

10-year avg

140.90

Supernus Pharmaceuticals, Inc. (SUPN) PE Ratio vs. Peers

How is SUPN’s PE Ratio compared to its peers?

Supernus Pharmaceuticals, Inc.’s PE Ratio is greater than Prestige Consumer Healthcare Inc. (20.46), greater than Evotec SE (-4.46), greater than Collegium Pharmaceutical, Inc. (10.91), greater than Deciphera Pharmaceuticals, Inc. (-11.74), greater than Eagle Pharmaceuticals, Inc. (0.34), greater than ANI Pharmaceuticals, Inc. (-155.73), less than Phibro Animal Health Corporation (55.24), greater than Pacira BioSciences, Inc. (-8.92), greater than Dr. Reddy's Laboratories Limited (3.74), greater than Silver Spike Investment Corp. (13.39), greater than Regencell Bioscience Holdings Limited (-15.65),

Build a custom stock screener for Supernus Pharmaceuticals, Inc. (SUPN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Supernus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Supernus Pharmaceuticals, Inc. (SUPN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Supernus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Supernus Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Supernus Pharmaceuticals, Inc. (SUPN)?

What is the highest PE Ratio for Supernus Pharmaceuticals, Inc. (SUPN)?

What is the 3-year average PE Ratio for Supernus Pharmaceuticals, Inc. (SUPN)?

What is the 5-year average PE Ratio for Supernus Pharmaceuticals, Inc. (SUPN)?

How does the current PE Ratio for Supernus Pharmaceuticals, Inc. (SUPN) compare to its historical average?